Skip to main content
SpringerLink
Log in
Book cover

Management of Breast Diseases pp 425–449Cite as

Metastatic Breast Cancer

  • Chapter

Abstract

Metastatic breast cancer is a leading cause of morbidity and mortality that needs to be understood and conquered. Although fewer than 10% of patients with breast cancer initially present with the metastatic disease, it will eventually develop in a substantial proportion of them [1]. Therapy for metastatic breast cancer remains palliative. The average survival time after the diagnosis of metastatic breast cancer is 24 months, although it varies widely according to the metastatic site, biological characteristics, patient condition and treatment [1]. The median survival time traditionally has been lower for patients with visceral disease (6–13 months) compared with those with bone-only disease (18–30 months). There has been recent epidemiological data to suggest improvement in breast cancer mortality in the past 15 years in the United Kingdom and the United States [2]. One of the reports demonstrated that after adjustment of several factors, similar cohort of women diagnosed with metastatic breast cancer in late 1990s compared with early 1990s, had better survival by 30%.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ellis MJ, Hegg D, Lippman ME (2000) Treatment of metastatic breast cancer, in diseases of the breast. Lippincott Williams and Wilkins, Philadelphia, pp 749–97

    Google Scholar 

  2. Chia SK et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 110(5):973–9

    PubMed  Google Scholar 

  3. Amar S, Roy V, Perez EA (2009) Treatment of metastatic breast cancer: looking toward the future. Breast Cancer Res Treat. 114(3):413–22

    PubMed  Google Scholar 

  4. Olin JJ, Muss HB. New strategies for managing metastatic breast cancer. Oncology (Williston Park). 2000;14(5):629–41; discussion 642–4, 647–8

    CAS  Google Scholar 

  5. Pritchard KI (2003) Endocrine therapy of advanced disease: analysis and implications of the existing data. Clin Cancer Res. 9(1 Pt 2):460S–7S

    CAS  PubMed  Google Scholar 

  6. Pritchard KI et al (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep. 64(6–7):787–96

    CAS  PubMed  Google Scholar 

  7. Crump M et al (1997) An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first-line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat. 44(4):201–10

    CAS  PubMed  Google Scholar 

  8. Sawka CA et al (1997) A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA. 1. Breast Cancer Res Treat. 44(3):211–5

    CAS  PubMed  Google Scholar 

  9. Burger CW, Prinssen HM, Kenemans P (1996) LHRH agonist treatment of breast cancer and gynecological malignancies: a review. Eur J Obstet Gynecol Reprod Biol. 67(1):27–33

    CAS  PubMed  Google Scholar 

  10. Taylor CW et al (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 16(3):994–9

    CAS  PubMed  Google Scholar 

  11. Plotkin D et al (1978) Tamoxifen flare in advanced breast cancer. JAMA. 240(24):2644–6

    CAS  PubMed  Google Scholar 

  12. Klijn JG et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 19(2):343–53

    CAS  PubMed  Google Scholar 

  13. Sinha S et al (1998) Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat. Breast Cancer Res Treat. 48(1):45–51

    CAS  PubMed  Google Scholar 

  14. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med. 348(24):2431–42

    CAS  PubMed  Google Scholar 

  15. Higgins MJ, Davidson NE (2009) What is the current status of ovarian suppression/ablation in women with premenopausal early stage breast cancer? Curr Oncol Rep. 11(1):45–50

    CAS  PubMed  Google Scholar 

  16. Smith IE et al (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 24(16):2444–7

    CAS  PubMed  Google Scholar 

  17. Grodin JM, Siiteri PK, MacDonald PC (1973) Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab. 36(2):207–14

    CAS  PubMed  Google Scholar 

  18. Mouridsen H et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 19(10):2596–606

    CAS  PubMed  Google Scholar 

  19. Bonneterre J et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma. Cancer. 92(9):2247–58

    CAS  PubMed  Google Scholar 

  20. Nabholtz JM et al (2003) Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer. 39(12):1684–9

    CAS  PubMed  Google Scholar 

  21. Briest S, Davidson NE (2007) Aromatase inhibitors for breast cancer. Rev Endocr Metab Disord. 8(3):215–28

    CAS  PubMed  Google Scholar 

  22. Bonneterre J et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol. 18(22):3748–57

    CAS  PubMed  Google Scholar 

  23. Mouridsen H et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 21(11):2101–9

    CAS  PubMed  Google Scholar 

  24. Nabholtz JM et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 18(22):3758–67

    CAS  Google Scholar 

  25. Paridaens RJ et al (2008) Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 26(30):4883–90

    CAS  PubMed  Google Scholar 

  26. Vergote I et al (2000) Randomized study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer. 36(Suppl 4):S84–5

    Google Scholar 

  27. Chia S, Gradishar W (2008) Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer. Breast. 17(Suppl 3):S16–21

    Google Scholar 

  28. Mauriac L et al (2003) Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer. 39(9):1228–33

    CAS  PubMed  Google Scholar 

  29. Chia S et al (2008) Double-blind, randomized placebo-controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 26(10):1664–70

    CAS  PubMed  Google Scholar 

  30. Buzdar AU (2008) Fulvestrant-a novel estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc). 44(9):679–92

    CAS  Google Scholar 

  31. Ellis MJ, Dehdahti F, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Jeffe DB, Gao F, Fleming G, Silverman P, Dickler M, Carey L, Marcom PK Siteman Cancer Center, St Louis; University of Chicago, Chicago; Case Western Reserve University, Cleveland; MSKCC, New York; UNC, Chapel Hill: Duke University, Durham. A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor-positive aromatase inhibitor resistant advanced breast cancer. In San Antonio Breast Cancer Symposium. San Antonio; 2008

    Google Scholar 

  32. Bernard-Marty C, Cardoso F, Piccart MJ (2004) Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist. 9(6):617–32

    PubMed  Google Scholar 

  33. Saloustros E, Mavroudis D, Georgoulias V (2008) Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother. 9(15):2603–16

    CAS  PubMed  Google Scholar 

  34. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med. 332(15):1004–14

    CAS  PubMed  Google Scholar 

  35. Jatoi I. Manual of breast diseases. In: Jatoi I, editor. Philadelphia: Lippincott Williams and Wilkins; 2002

    Google Scholar 

  36. Winer EP et al (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 22(11):2061–8

    CAS  PubMed  Google Scholar 

  37. Seidman AD et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 26(10):1642–9

    CAS  PubMed  Google Scholar 

  38. Verrill M. Anglo-Ceptic IV: first results of a UK National Cancer Research Network randomized phase III (pharmacogenetic trial of weekly compared to 3-weekly paclitaxel in patients with locally advanced or metastatic breast cancer. In Proceedings ASCO annual meeting. Chicago, Illinois; 2007

    Google Scholar 

  39. Diaz JF, Andreu JM (1993) Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry. 32(11):2747–55

    CAS  PubMed  Google Scholar 

  40. Hanauske AR et al (1992) Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs. 3(2):121–4

    Article  CAS  PubMed  Google Scholar 

  41. Baur M et al (2008) A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer. J Cancer Res Clin Oncol. 134(2):125–35

    CAS  PubMed  Google Scholar 

  42. Dieras V et al (1996) A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer. 74(4):650–6

    CAS  PubMed  Google Scholar 

  43. Chan S et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 17(8):2341–54

    CAS  PubMed  Google Scholar 

  44. Nabholtz JM et al (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 17(5):1413–24

    CAS  PubMed  Google Scholar 

  45. Sjostrom J et al (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer. 35(8):1194–201

    CAS  PubMed  Google Scholar 

  46. Harvey V et al (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol. 24(31):4963–70

    CAS  PubMed  Google Scholar 

  47. Rivera E et al (2008) Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 112(7):1455–61

    CAS  PubMed  Google Scholar 

  48. Burstein HJ et al (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 18(6):1212–9

    CAS  PubMed  Google Scholar 

  49. Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol. 13(10):2643–55

    CAS  PubMed  Google Scholar 

  50. Desai N et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 12(4):1317–24

    CAS  PubMed  Google Scholar 

  51. Henderson IC, Bhatia V (2007) Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther. 7(7):919–43

    CAS  PubMed  Google Scholar 

  52. Gradishar WJ et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 23(31):7794–803

    CAS  PubMed  Google Scholar 

  53. Jones SE et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 23(24):5542–51

    CAS  PubMed  Google Scholar 

  54. Gradishar W. A randomized phase II trial of Qw or Q3w of ABI 007 (ABX) vs. Q3w solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). In 29th Annual Breast Cancer Symposium. San Antonio, Texas: 2006

    Google Scholar 

  55. Lowenthal EA, Carpenter JT Jr (1995) The use of anthracyclines in the adjuvant treatment of breast cancer. Cancer Treat Rev. 21(3):199–214

    CAS  PubMed  Google Scholar 

  56. Paridaens R et al (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and treatment of cancer randomized study with cross-over. J Clin Oncol. 18(4):724–33

    CAS  PubMed  Google Scholar 

  57. Bontenbal M et al (1998) Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. Br J Cancer. 77(12):2257–63

    CAS  PubMed  Google Scholar 

  58. Brambilla C et al (1986) Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep. 70(2):261–6

    CAS  PubMed  Google Scholar 

  59. Jain KK et al (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 3(6):818–26

    CAS  PubMed  Google Scholar 

  60. Langley RE et al (2005) Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol. 23(33):8322–30

    CAS  PubMed  Google Scholar 

  61. Pacilio C et al (2006) Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. Br J Cancer. 94(9):1233–6

    CAS  PubMed  Google Scholar 

  62. Lorusso V, Manzione L, Silvestris N (2007) Role of liposomal anthracyclines in breast cancer. Ann Oncol. 18(Suppl 6):vi70–3

    PubMed  Google Scholar 

  63. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58(7):1408–16

    CAS  PubMed  Google Scholar 

  64. Gabizon A et al (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54(4):987–92

    CAS  PubMed  Google Scholar 

  65. O’Brien ME et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 15(3):440–9

    PubMed  Google Scholar 

  66. Dumontet C, Jordan MA, Lee FF (2009) Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther. 8(1):17–25

    CAS  PubMed  Google Scholar 

  67. Lee FY et al (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 7(5):1429–37

    CAS  PubMed  Google Scholar 

  68. Roche H et al (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 25(23):3415–20

    CAS  PubMed  Google Scholar 

  69. Perez EA et al (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 22(14):2849–55

    CAS  PubMed  Google Scholar 

  70. Perez EA et al (2007) Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 25(23):3407–14

    CAS  PubMed  Google Scholar 

  71. Oshaughnessy JA et al (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol. 12(9):1247–54

    Google Scholar 

  72. Blum JL et al (2001) Multicenter. Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 92(7):1759–68

    CAS  PubMed  Google Scholar 

  73. Ershler WB (2006) Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist. 11(4):325–35

    CAS  PubMed  Google Scholar 

  74. Wirk B, Perez E (2006) Role of gemcitabine in breast cancer management: an update. Semin Oncol. 33(1 Suppl 2):S6–14

    Google Scholar 

  75. Albain KS et al (2008) Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 26(24):3950–7

    PubMed  Google Scholar 

  76. Zelek L et al (2001) Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 92(9):2267–72

    CAS  PubMed  Google Scholar 

  77. Potmesil M (1994) Camptothecins: from bench research to hospital wards. Cancer Res. 54(6):1431–9

    CAS  PubMed  Google Scholar 

  78. Baltali E et al (2002) Paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast cancer. Tumori. 88(3):200–3

    CAS  PubMed  Google Scholar 

  79. Biganzoli L et al (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and treatment of cancer 10961 multicenter phase III trial. J Clin Oncol. 20(14):3114–21

    CAS  PubMed  Google Scholar 

  80. Biganzoli L et al (2003) Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for research and treatment of cancer multicenter trial. Cancer. 97(1):40–5

    CAS  PubMed  Google Scholar 

  81. Cassier PA et al (2008) A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat. 109(2):343–50

    CAS  PubMed  Google Scholar 

  82. Valero V, Hortobagyi GN (2003) Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol. 21(6):959–62

    PubMed  Google Scholar 

  83. Jassem J et al (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 19(6):1707–15

    CAS  PubMed  Google Scholar 

  84. Sledge GW et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy, for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 21(4):588–92

    PubMed  Google Scholar 

  85. Bontenbal M et al (2005) Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch community setting trial for the clinical trial group of the comprehensive cancer centre. J Clin Oncol. 23(28):7081–8

    CAS  PubMed  Google Scholar 

  86. Sparano J, Makhson-Anatoly N, Semiglazov V, Tjulandin S, Balashova O, Bondarenko I, Bogdanova N, Chatikhine V, Zhuang S, Xiu L, Yuan Z, Rackoff W Albert Einstein Coll of Med, New York; City Onc Hosp #62, Moscow, Russian Federation; NN Blokhin Can Res Cntr, Moscow, Russian Federation; Regional Onc Dispensary, Dnepropetrovsk, Ukraine; State Med Acad, Dnepropetrovsk. Ukraine; PA Herzen Onc Res Inst, Moscow, Russian Federation; OrthoBiotech Onc R and D, J and JPRD, Raritan. Pegylated liposomal doxorubicin (PLD) plus docetaxel significantly improves time to progression (TTP) compared with docetaxel (D) monotherapy in patients with advanced breast cancer (ABC) treated with adjuvant anthracycline: results from a randomized phase 3 study. In San Antonio Breast Cancer Symposium. San Antonio; 2008

    Google Scholar 

  87. Piccart-Gebhart MJ et al (2008) Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 26(12):1980–6

    CAS  PubMed  Google Scholar 

  88. Fountzilas G et al (2004) Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 15(10):1517–26

    CAS  PubMed  Google Scholar 

  89. Perez EA et al (2000) A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 88(1):124–31

    CAS  PubMed  Google Scholar 

  90. Fountzilas G et al (2008) A randomized phase III study comparing three anthracycline-free taxane-based regimens as first-line chemotherapy in metastatic breast cancer: A Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat. 115(1):87–99

    PubMed  Google Scholar 

  91. O’Shaughnessy J et al (2007) Superior survival with capecitabine plus docetaxel combination therapy in anthracyclinepretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 20(12):2812–23

    Google Scholar 

  92. Chan S et al (2009) Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol. 27(11):1753–60

    CAS  PubMed  Google Scholar 

  93. Thomas ES et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 25(33):5210–7

    CAS  PubMed  Google Scholar 

  94. Rugo HS, Thomas ES, Lee RK, Fein LE, Peck R, Verrill M. UCSF Comprehensive Cancer Center, San Francisco, CA; Kaiser Permanente, Oakland, CA; The St. Lukes Medical Center, Quezon City, Philippines; The Centro de Oncologia Rosario, Sante Fe, Argentina; Bristol-Myers Squibb, Wallingford, CT; Northern Institute for Canacer Researcy, Newcastle upon Tyne, United Kingdom. Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. In San Antonio Breast Cancer Symposium. San Antonio; 2007

    Google Scholar 

  95. Perez EA (1999) HER-2 as a prognostic, predictive, and therapeutic target in breast cancer. Cancer Control. 6(3):233–40

    PubMed  Google Scholar 

  96. Nielsen DL, Andersson M, Kamby C (2009) HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev. 35(2):121–36

    CAS  PubMed  Google Scholar 

  97. Orman JS, Perry CM (2007) Trastuzumab: in HER2 and hormone receptor co-positive metastatic breast cancer. Drugs. 67(18):2781–9

    CAS  PubMed  Google Scholar 

  98. Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Jones A. Cross Cancer Institute, Edmonton, Canada; Chaim Sheba Medical Center, Tel Hashomer, Israel; Krankenanstalt Mutterhaus der Borromaerinnen, Trier, Germany; Kidwai Memorial Institute of Oncology, Bangalore, India; Rajiv Gandhi Cancer Institute, New Delhi, India; Christie Hospital NHS Trust, Manchester, United Kingdom; Russian Cancer Research Center, Moscow, Russian Federation; F Hoffmann-La Roche, Basel, Switzerland; Royal Free Hospital, London, United Kingdom. Trastumumab prolongs progression-free survival in hormonedependent and HER2-positive metastatic breast cancer. In San Antonio Breast Cancer Symposium. San Antonio; 2006

    Google Scholar 

  99. Clemens M.B.K., Mackey JR, Bapsy P, Vaid A, Wardley A, Tjulandin S, Révil C, Lehle M, Jones A. Trastuzumab plus anastrozole may prolong overall survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer: Results of a post-hoc analysis from the TAnDEM study. In 2007 Breast Cancer Symposium; 2007

    Google Scholar 

  100. Pegram MD et al (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 96(10):739–49

    Article  CAS  PubMed  Google Scholar 

  101. Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344(11):783–92

    CAS  PubMed  Google Scholar 

  102. Marty M et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 23(19):4265–74

    CAS  PubMed  Google Scholar 

  103. Perez EA et al (2005) Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 6(5):425–32

    CAS  PubMed  Google Scholar 

  104. Metro G, Mottolesse M, Fabi A (2008) HER2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother. 9(15):2583–601

    CAS  PubMed  Google Scholar 

  105. Tripathy D et al (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 22(6):1063–70

    CAS  PubMed  Google Scholar 

  106. Bartsch R et al (2006) Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer. 6:63

    PubMed  Google Scholar 

  107. Spector N (2008) Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab. Clin Breast Cancer. 8(Suppl 3):S94–9

    Google Scholar 

  108. Nelson MH, Dolder CR (2006) Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother. 40(2):261–9

    CAS  PubMed  Google Scholar 

  109. Geyer CE et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 355(26):2733–43

    CAS  PubMed  Google Scholar 

  110. Di Leo A et al (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 26(34):5544–52

    PubMed  Google Scholar 

  111. Johnston S, O’Rourke L, Wang W, Pegram M, Press MF, Maltzman J. Correlation of tumor burden, liver and bone metastasis with serum extracellular domain HER2 expression in front-line metastatic breast cancer. In San Antonio Breast Cancer Symposium. San Antonio; 2008

    Google Scholar 

  112. Gomez HL et al (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 26(18):2999–3005

    CAS  PubMed  Google Scholar 

  113. Clayton AJ et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 91(4):639–43

    CAS  PubMed  Google Scholar 

  114. Lin NU et al (2009) Multicenter phase II study of lapatinib in patients, with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 15(4):1452–9

    CAS  PubMed  Google Scholar 

  115. Fox SB, Generali DG, Harris AL (2007) Breast tumor angiogenesis. Breast Cancer Res. 9(6):216

    PubMed  Google Scholar 

  116. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307(5706):58–62

    CAS  PubMed  Google Scholar 

  117. Miller KD et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 23(4):792–9

    CAS  PubMed  Google Scholar 

  118. Miller K et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357(26):2666–76

    CAS  PubMed  Google Scholar 

  119. Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 19(4):1195–206

    CAS  PubMed  Google Scholar 

  120. Miles D, Chan A, ROmieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer: AVADO, in ASCO. Chicago, Illinois; 2008

    Google Scholar 

  121. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol. 205(2):275–92

    CAS  PubMed  Google Scholar 

  122. Farquhar C, et al. High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev. 2005(3): CD003142

    Google Scholar 

  123. Mehrotra B (2009) Bisphosphonates-role in cancer therapies. J Oral Maxillofac Surg. 67(5 Suppl):19–26

    PubMed  Google Scholar 

  124. Roodman GD (2001) Biology of osteoclast activation in cancer. J Clin Oncol. 19(15):3562–71

    CAS  PubMed  Google Scholar 

  125. Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 83(9):1032–45

    CAS  PubMed  Google Scholar 

  126. Paterson AH et al (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 11(1):59–65

    CAS  PubMed  Google Scholar 

  127. Hortobagyi GN et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 335(24):1785–91

    CAS  PubMed  Google Scholar 

  128. Conte PF et al (1996) Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 14(9):2552–9

    CAS  PubMed  Google Scholar 

  129. Rosen LS et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 100(1):36–43

    CAS  PubMed  Google Scholar 

  130. Hillner BE et al (2000) American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol. 18(6):1378–91

    CAS  PubMed  Google Scholar 

  131. JD W (2008) Cancer: principles and practice of oncology. 8th ed. Hellman S, DeVita VT Jr, Rosenberg SA editors. Philadelphia, PA: Lippincott Williams and Wilkins

    Google Scholar 

  132. Hortobagyi GN (2002) Can we cure limited metastatic breast cancer? J Clin Oncol. 20(3):620–3

    PubMed  Google Scholar 

  133. Le Scodan R et al (2009) Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol. 27(9):1375–81

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, 32224, USA

    Tejal A. Patel & Edith A. Perez

Authors
  1. Tejal A. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edith A. Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edith A. Perez .

Editor information

Editors and Affiliations

  1. Breast Care Center National Naval Medical Center, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814, USA

    Ismail Jatoi (Head) (Head)

  2. Women’s Hospital, University of Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany

    Manfred Kaufmann (Breast Unit Director) (Breast Unit Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Patel, T.A., Perez, E.A. (2010). Metastatic Breast Cancer. In: Jatoi, I., Kaufmann, M. (eds) Management of Breast Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69743-5_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-69743-5_23

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-69742-8

  • Online ISBN: 978-3-540-69743-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation